Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 ...
Stay updated with Wall Street's weekly highlights: key inflation data, CoreWeave IPO, and earnings reports. Insights on ...
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback